Parathyroid hormone: A double-edged sword for bone metabolism

Trends in Endocrinology and Metabolism

Volumn 15, Issue 2, 2004, Pages 60-65

  Qin, Ling ^a   Raggatt, Liza J ^a   Partridge, Nicola C ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; GLUCOCORTICOID; PARATHYROID HORMONE; PROTEIN FOS; SOMATOMEDIN;

BIOSYNTHESIS; BONE GROWTH; BONE METABOLISM; CALCIUM METABOLISM; CATABOLISM; CELL DIFFERENTIATION; CELL GROWTH; HORMONE ACTION; HORMONE RELEASE; HYPERCALCEMIA; KINETICS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 1342329522     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2004.01.006     Document Type: Review

References (49)

1. Tam C.S., et al. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology. 110:1982;506-512.
2. Kostenuik P.J., et al. Skeletal unloading causes resistance of osteoprogenitor cells to parathyroid hormone and to insulin-like growth factor-I. J. Bone Miner. Res. 14:1999;21-31.
3. Nishida S., et al. Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone. 15:1994;717-723.
4. Dobnig H., Turner R.T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology. 136:1995;3632-3638.
5. Leaffer D., et al. Modulation of osteogenic cell ultrastructure by RS-23581, an analog of human parathyroid hormone (PTH)-related peptide-(1-34), and bovine PTH-(1-34). Endocrinology. 136:1995;3624-3631.
6. Dobnig H., Turner R.T. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology. 138:1997;4607-4612.
7. Hodsman A.B., et al. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J. Clin. Invest. 91:1993;1138-1148.
8. Schmidt I.U., et al. Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. Endocrinology. 136:1995;5127-5134.
9. Meng X.W., et al. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. J. Bone Miner. Res. 11:1996;421-429.
10. Onyia J.E., et al. In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats. Bone. 17:1995;479-484.
11. Qin L., et al. Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics. J. Biol. Chem. 278:2003;19723-19731.
12. Jilka R.L., et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest. 104:1999;439-446.
13. Stanislaus D., et al. In vivo regulation of apoptosis in metaphyseal trabecular bone of young rats by synthetic human parathyroid hormone (1-34) fragment. Bone. 27:2000;209-218.
14. Chen H.L., et al. Parathyroid hormone and parathyroid hormone-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells. J. Biol. Chem. 277:2002;19374-19381.
15. Miao D., et al. Parathyroid hormone is essential for normal fetal bone formation. J. Clin. Invest. 109:2002;1173-1182.
16. Lacey D.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:1998;165-176.
17. Yasuda H., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U. S. A. 95:1998;3597-3602.
18. Ma Y.L., et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology. 142:2001;4047-4054.
19. Locklin R.M., et al. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J. Cell. Biochem. 89:2003;180-190.
20. Ma Y.L., et al. New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology. 144:2003;2008-2015.
21. Black D.M., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349:2003;1207-1215.
22. Finkelstein J.S., et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. 349:2003;1216-1226.
23. Erclik M.S., Mitchell J. The role of protein kinase C-δ in PTH stimulation of IGF-binding protein-5 mRNA in UMR-106-01 cells. Am. J. Physiol. Endocrinol. Metab. 282:2002;E534-E541.
24. Wu Y., Kumar R. Parathyroid hormone regulates transforming growth factor β1 and β2 synthesis in osteoblasts via divergent signaling pathways. J. Bone Miner. Res. 15:2000;879-884.
25. Rixon R.H., et al. Parathyroid hormone fragments may stimulate bone growth in ovariectomized rats by activating adenylyl cyclase. J. Bone Miner. Res. 9:1994;1179-1189.
26. Armamento-Villareal R., et al. An intact N terminus is required for the anabolic action of parathyroid hormone on adult female rats. J. Bone Miner. Res. 12:1997;384-392.
27. Komori T., et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 89:1997;755-764.
28. Krishnan V., et al. Parathyroid hormone bone anabolic action requires Cbfa1/Runx2-dependent signaling. Mol. Endocrinol. 17:2003;423-435.
29. Selvamurugan N., et al. Parathyroid hormone regulation of the rat collagenase-3 promoter by protein kinase A-dependent transactivation of core binding factor α1. J. Biol. Chem. 275:2000;5037-5042.
30. Partridge N.C., et al. Hormonal regulation of the production of collagenase and a collagenase inhibitor activity by rat osteogenic sarcoma cells. Endocrinology. 120:1987;1956-1962.
31. Noda M., et al. Cyclic AMP-mediated stabilization of osteocalcin mRNA in rat osteoblast-like cells treated with parathyroid hormone. J. Biol. Chem. 263:1988;18574-18577.
32. Garcia T., et al. Behavior of osteoblast, adipocyte, and myoblast markers in genome-wide expression analysis of mouse calvaria primary osteoblasts in vitro. Bone. 31:2002;205-211.
33. Raouf A., et al. Lumican is a major proteoglycan component of the bone matrix. Matrix Biol. 21:2002;361-367.
34. Raouf A., Seth A. Discovery of osteoblast-associated genes using cDNA microarrays. Bone. 30:2002;463-471.
35. Vaes B.L., et al. Comprehensive microarray analysis of bone morphogenetic protein 2-induced osteoblast differentiation resulting in the identification of novel markers for bone development. J. Bone Miner. Res. 17:2002;2106-2118.
36. Beck G.R. Jr, et al. Gene array analysis of osteoblast differentiation. Cell Growth Differ. 12:2001;61-83.
37. Flannery P.J., Spurney R.F. Domains of the parathyroid hormone (PTH) receptor required for regulation by G protein-coupled receptor kinases (GRKs). Biochem. Pharmacol. 62:2001;1047-1058.
38. Vilardaga J.P., et al. Internalization determinants of the parathyroid hormone receptor differentially regulate β-arrestin/receptor association. J. Biol. Chem. 277:2002;8121-8129.
39. Spurney R.F., et al. Anabolic effects of a G protein-coupled receptor kinase inhibitor expressed in osteoblasts. J. Clin. Invest. 109:2002;1361-1371.
40. Fujita T., et al. New signaling pathway for parathyroid hormone and cyclic AMP action on extracellular-regulated kinase and cell proliferation in bone cells. Checkpoint of modulation by cyclic AMP. J. Biol. Chem. 277:2002;22191-22200.
41. Demiralp B., et al. Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos. Endocrinology. 143:2002;4038-4047.
42. Bikle D.D., et al. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J. Bone Miner. Res. 17:2002;1570-1578.
43. Miyakoshi N., et al. Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology. 142:2001;4349-4356.
44. Gonzalez E.A., Martin K.J. Coordinate regulation of PTH/PTHrP receptors by PTH and calcitriol in UMR 106-01 osteoblast-like cells. Kidney Int. 50:1996;63-70.
45. Ishizuya T., et al. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J. Clin. Invest. 99:1997;2961-2970.
46. Koh A.J., et al. 3′,5′-Cyclic adenosine monophosphate activation in osteoblastic cells: effects on parathyroid hormone-1 receptors and osteoblastic differentiation in vitro. Endocrinology. 140:1999;3154-3162.
47. McCarthy T.L., Centrella M. Local IGF-I expression and bone formation. Growth Horm. IGF Res. 11:2001;213-219.
48. Lotinun S., et al. Triazolopyrimidine (trapidil), a platelet-derived growth factor antagonist, inhibits parathyroid bone disease in an animal model for chronic hyperparathyroidism. Endocrinology. 144:2003;2000-2007.
49. 2+ receptor antagonists that stimulate secretion of parathyroid hormone. J. Pharmacol. Exp. Ther. 299:2001;323-331.